HUP0301356A2 - Új, DPPIV-gyel rokon szerin proteáz gének - Google Patents

Új, DPPIV-gyel rokon szerin proteáz gének

Info

Publication number
HUP0301356A2
HUP0301356A2 HU0301356A HUP0301356A HUP0301356A2 HU P0301356 A2 HUP0301356 A2 HU P0301356A2 HU 0301356 A HU0301356 A HU 0301356A HU P0301356 A HUP0301356 A HU P0301356A HU P0301356 A2 HUP0301356 A2 HU P0301356A2
Authority
HU
Hungary
Prior art keywords
proteins
dppiv
subject
serine protease
genes related
Prior art date
Application number
HU0301356A
Other languages
English (en)
Inventor
Karen O. Akinsanya
Jean-Louis Junien
Steve Qi
Pierre J. M. Riviere
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HUP0301356A2 publication Critical patent/HUP0301356A2/hu
Publication of HUP0301356A3 publication Critical patent/HUP0301356A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)

Abstract

A találmány tárgyát új fehérjék vagy polipeptidek képezik, amelyekszignifikáns szekvencia-homológiát mutatnak a DPPIV-gyel, valamint atalálmány tárgyát képezik az ezeket kódoló nukleinsavak, az olyansejtek, amiket úgy módosítottak az említett nukleinsavakkal, hogyexpresszálják ezeket a fehérjéket, az említett fehérjék elleniellenanyagok, szűrővizsgálati módszerek, amelyekkel új terápiáságenseket lehet felfedezni, amelyek gátolják ezeknek a fehérjéknek,vagy a rokon fehérjéknek az aktivitását, és a találmány tárgyátképezik az ilyen szűrővizsgálati módszerrel felfedezett terápiáságensek, és az új terápiás kezelések is. Ó
HU0301356A 2000-10-12 2001-10-12 Novel serine protease genes related to dppiv HUP0301356A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24011700P 2000-10-12 2000-10-12
PCT/US2001/031874 WO2002031134A2 (en) 2000-10-12 2001-10-12 Novel serine protease genes related to dppiv

Publications (2)

Publication Number Publication Date
HUP0301356A2 true HUP0301356A2 (hu) 2003-10-28
HUP0301356A3 HUP0301356A3 (en) 2010-03-29

Family

ID=22905181

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301356A HUP0301356A3 (en) 2000-10-12 2001-10-12 Novel serine protease genes related to dppiv

Country Status (18)

Country Link
US (2) US6844180B2 (hu)
EP (1) EP1346033A2 (hu)
JP (1) JP2004528812A (hu)
KR (1) KR100875221B1 (hu)
CN (2) CN101270362A (hu)
AU (2) AU1313802A (hu)
CA (1) CA2425001A1 (hu)
CZ (1) CZ20031301A3 (hu)
HK (1) HK1078104A1 (hu)
HU (1) HUP0301356A3 (hu)
IL (2) IL155245A0 (hu)
MX (1) MXPA03003191A (hu)
NO (1) NO329842B1 (hu)
NZ (1) NZ525443A (hu)
PL (1) PL366005A1 (hu)
RU (1) RU2305133C2 (hu)
WO (1) WO2002031134A2 (hu)
ZA (1) ZA200303306B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
JP4748908B2 (ja) * 1999-09-10 2011-08-17 ザ・ユニバーシティ・オブ・シドニー ジペプチジルペプチダーゼ
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
AUPR107800A0 (en) * 2000-10-27 2000-11-23 University Of Sydney, The Peptide and nucleic acid molecule ii
GB0101760D0 (en) * 2001-01-23 2001-03-07 Glaxo Group Ltd Novel protein
AU2002249453A1 (en) * 2001-04-24 2002-11-05 Isis Innovation Ltd Enzyme and snp marker for disease
CN100341572C (zh) 2001-05-11 2007-10-10 得克萨斯州立大学董事会 抗cd26单克隆抗体作为对与表达cd26的细胞相关疾病的治疗
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US6709651B2 (en) 2001-07-03 2004-03-23 B.M.R.A. Corporation B.V. Treatment of substance P-related disorders
WO2003057916A2 (en) * 2002-01-09 2003-07-17 Riken Cancer profiles
EP1528931B1 (en) 2002-08-09 2008-05-07 Prosidion Ltd. Dipeptidyl peptidase iv inhibitors for decreasing the rate of chronic weight gain
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
BRPI0413452A (pt) 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005106487A1 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 9 (dpp9)
WO2005106021A1 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 8 (dpp8)
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060063719A1 (en) * 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
EP2805953B1 (en) * 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
JP5122462B2 (ja) 2005-09-16 2013-01-16 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
WO2007047205A2 (en) * 2005-10-11 2007-04-26 Amano Enzyme Usa Co., Ltd. Enzyme inhibitors of pai-1
WO2007054577A1 (en) 2005-11-14 2007-05-18 Probiodrug Ag Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MX2008013130A (es) 2006-04-12 2008-11-19 Probiodrug Ag Inhibidores de enzima.
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101259119B (zh) * 2007-03-08 2010-05-19 上海市计划生育科学研究所 一种丝氨酸蛋白酶抑制剂及其衍生物在生育调节中的应用
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US9593148B2 (en) * 2012-11-02 2017-03-14 Georg-August-Universitat Gottingen Stiftung Offentlichen Rechts DPP8 and DPP9 peptide inhibitors
US11427814B2 (en) 2019-03-26 2022-08-30 Encodia, Inc. Modified cleavases, uses thereof and related kits
KR102567902B1 (ko) * 2019-03-26 2023-08-18 엔코디아, 인코포레이티드 변형된 클리바아제, 이의 용도 및 관련 키트

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
AU2501200A (en) 1999-01-11 2000-08-01 Incyte Pharmaceuticals, Inc. Human peptidases
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
JP4748908B2 (ja) 1999-09-10 2011-08-17 ザ・ユニバーシティ・オブ・シドニー ジペプチジルペプチダーゼ
CN1307128A (zh) 2000-01-26 2001-08-08 上海博道基因技术有限公司 一种新的多肽——人二肽氨肽酶28和编码这种多肽的多核苷酸
WO2001098468A2 (en) * 2000-06-16 2001-12-27 Incyte Genomics, Inc. Proteases

Also Published As

Publication number Publication date
IL155245A0 (en) 2003-11-23
HK1078104A1 (en) 2006-03-03
CA2425001A1 (en) 2002-04-18
US20050059081A1 (en) 2005-03-17
MXPA03003191A (es) 2004-12-03
US20020115843A1 (en) 2002-08-22
WO2002031134A2 (en) 2002-04-18
KR100875221B1 (ko) 2008-12-19
CZ20031301A3 (cs) 2003-10-15
US6844180B2 (en) 2005-01-18
PL366005A1 (en) 2005-01-24
WO2002031134A3 (en) 2003-07-17
AU2002213138B2 (en) 2006-07-20
NO20031702D0 (no) 2003-04-11
CN101270362A (zh) 2008-09-24
JP2004528812A (ja) 2004-09-24
CN100354417C (zh) 2007-12-12
HUP0301356A3 (en) 2010-03-29
KR20030038815A (ko) 2003-05-16
RU2305133C2 (ru) 2007-08-27
NO20031702L (no) 2003-05-15
CN1636061A (zh) 2005-07-06
NZ525443A (en) 2006-04-28
NO329842B1 (no) 2011-01-10
ZA200303306B (en) 2004-08-12
EP1346033A2 (en) 2003-09-24
US7157241B2 (en) 2007-01-02
IL155245A (en) 2010-04-15
AU1313802A (en) 2002-04-22

Similar Documents

Publication Publication Date Title
HUP0301356A2 (hu) Új, DPPIV-gyel rokon szerin proteáz gének
HUP0300369A2 (hu) Többértékű antitestek és alkalmazásuk
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE468394T1 (de) Vermischen von heterologen dns-sequenzen
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
DE602005011486D1 (de) Säure-pilzprotease bei der fermentation von nichtlöslichen stärkesubstraten
ATE500323T1 (de) Subtilisin-variante
ATE510011T1 (de) Neue pilzproteine und diese codierende nukleinsäuren
DE60142226D1 (de) Pilz transkriptionsaktivator zur verwendung in verfahren zur herstellung von polypeptiden
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
DE69329195D1 (de) Rekombinante dna moleküle die aminopeptidase enzyme kodieren und ihre anwendung für die herstellung von impfstoffen gegen helminth infektionen
HUP9800329A2 (hu) Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására
WO2003076561A3 (en) Recombinase fusion protein with enhanced cellular uptake
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
AR046180A1 (es) Metodo para producir proteinas gamma carboxiladas y uso terapeutico de las mismas
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
HUP0203221A2 (hu) A lignin bioszintézisében résztvevő enzimeket kódoló gének és alkalmazásuk
ATE271609T1 (de) Mch3, eine apoptosis-protease, kodierende nukleinsäuren und methoden zur verwendung
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees